Aptevo Therapeutics Inc (APVO) Expected to Post Earnings of -$0.32 Per Share

Wall Street brokerages expect Aptevo Therapeutics Inc (NASDAQ:APVO) to announce ($0.32) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Aptevo Therapeutics’ earnings. Aptevo Therapeutics posted earnings per share of $0.01 during the same quarter last year, which indicates a negative year-over-year growth rate of 3,300%. The company is expected to report its next quarterly earnings results on Friday, March 30th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full year earnings of $0.43 per share for the current financial year. For the next financial year, analysts expect that the business will report earnings of ($2.69) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Aptevo Therapeutics.

Several research firms have commented on APVO. Piper Jaffray Companies reiterated an “overweight” rating and issued a $6.00 target price on shares of Aptevo Therapeutics in a research report on Thursday, October 5th. ValuEngine upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 12th.

In other news, VP Randy Joe Maddux bought 25,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was purchased at an average cost of $2.76 per share, for a total transaction of $69,000.00. Following the completion of the transaction, the vice president now owns 25,000 shares of the company’s stock, valued at $69,000. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 15.60% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in shares of Aptevo Therapeutics by 8.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after acquiring an additional 78,109 shares during the last quarter. Precept Management LLC bought a new position in shares of Aptevo Therapeutics during the second quarter worth about $1,210,000. Finally, Legal & General Group Plc raised its position in shares of Aptevo Therapeutics by 11,751.3% during the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after acquiring an additional 390,379 shares during the last quarter. Hedge funds and other institutional investors own 32.13% of the company’s stock.

Aptevo Therapeutics (NASDAQ APVO) traded up $0.01 during trading on Tuesday, reaching $4.24. The company’s stock had a trading volume of 118,039 shares, compared to its average volume of 333,982. The company has a quick ratio of 7.67, a current ratio of 7.76 and a debt-to-equity ratio of 0.19. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.50.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://weekherald.com/2017/12/29/aptevo-therapeutics-inc-apvo-expected-to-post-earnings-of-0-32-per-share.html.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply